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Abstract 
Inappropriate sinus tachycardia (IST) is an incompletely understood condition characterised 
by an elevation in heart rate (HR) accompanied by wide ranging symptoms, in the absence 
of an underlying physiological stimulus. The condition often takes a chronic course with 
significant adverse effects on quality of life. Currently there is no effective treatment for IST. 
Beta-blockers, generally considered the cornerstone of treatment, are often ineffective and 
poorly tolerated. Ivabradine is a novel sinus node If “funny current” inhibitor which reduces 
the HR. It has been approved for the treatment of beta-blocker refractory chronic systolic 
heart failure and chronic stable angina, but more recently shown promise in the treatment 
of IST. This review provides an overview of IST prevalence and mechanisms, followed by an 
examination of the evidence for the role and efficacy of ivabradine in the treatment of IST.  
 
Keywords: Inappropriate sinus tachycardia; Ivabradine  
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Introduction  
Inappropriate sinus tachycardia is defined as a persistent non-paroxysmal elevation in the 
resting and exertional HR with no identifiable physiological or pathological stimulus(1). 
There is no formally accepted HR threshold for the definition of IST. This is, in part, related 
to the wide range of normal HR variation within the population, its dependency on age(2) 
and underlying physiological status. Population studies show that, in addition to an inverse 
correlation with age, mean intrinsic HR (HR under complete pharmacologic autonomic 
blockade or autonomic denervation) is independently associated with levels of physical 
activity, blood pressure, tobacco smoking, intake of caffeine and body height(3). The 2015 
Heart Rhythm Society expert consensus statement defines IST as a “sinus heart rate 
>100bpm at rest (with a mean 24-hour heart rate >90 bpm not due to primary causes) and 
associated distressing symptoms of palpitations”(1, 4, 5). Other commonly described 
symptoms include dizziness, light headedness, dyspnoea and pre-syncope.   
 
Prevalence and Clinical Course of IST 
An Icelandic study of randomly sampled patients from insurance registries for hypertension 
reimbursement, described the prevalence and course of IST using the above  definition(4). 
The largest of its kind, the study rigorously excluded differential diagnoses and mimics of 
the condition. However, the overall population was relatively small (604) and 149 subjects 
were on beta adrenoceptor antagonists for hypertension treatment. Of the 604 patient 
cohort, 7 fulfilled the definition for IST, yielding a prevalence of 1.16%. This is greater than 
the estimates for Wolff-Parkinson-White syndrome (0.15-0.31%)(6). No differences were 
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found between IST and control patients with regards to age, gender, smoking habits, alcohol 
intake, physical activity levels and adiposity. The mean age and 24-h ambulatory systolic 
pressure in the IST group was 47±7 years and 147±11 mmHg, respectively, noting the likely 
bias related to the cohort source (systemic arterial hypertension). After a mean follow-up of 
6.0±2.4 years, the outlook for the condition was found to be benign, particularly for the 
development of tachycardia-mediated cardiomyopathy and survival. However, at follow-up, 
there was persistence of symptoms, elevated resting HR and elevated average daily HR.  
 
Mechanisms in IST 
The trigger and mechanism for the tachycardia in IST is unknown. Expert anecdotal evidence 
has suggested halogenated hydrocarbon exposure as one possible cause, although this is 
unsubstantiated(7). Peripheral and central neurohormonal mediators of autonomic control 
or their receptors have been implicated, however this remains speculative(8, 9). Notably, an 
exaggerated HR response to isoprenaline infusion occurs in less than one third of 
patients(10). This observation and the relative inefficacy of beta-blockade have led some 
investigators to believe that the condition may represent a sinus node channelopathy rather 
than an abnormality of autonomic modulation(11). Some clinical studies have pointed 
towards an elevation in intrinsic HR mediated by ATP sensitive potassium channels in sinus 
node tissue(12). A small study has identified greater plasma levels of beta adrenoceptor 
antibodies in patients with IST as compared to controls(11). The presence of these 
antibodies has been hypothesised to result in receptor activation function and second 
messenger mediated calcium influx and depolarisation.  As yet there have been no reports 
of specific genetic abnormalities associated with IST. 
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Clinical Presentation and Diagnosis 
Inappropriate sinus tachycardia often presents non-specifically with symptoms including 
pre-syncope, syncope, dyspnoea, exercise intolerance, dizziness, light-headedness, 
weakness and palpitations either chronically or in a relapsing and remitting pattern. Their 
severity may vary from mild to significantly disabling, and importantly may not parallel the 
severity of the tachycardia.  
Essential to the diagnosis of IST is exclusion of underlying causes for an appropriate sinus 
tachycardia such as anaemia, cardiac failure, infection, stimulant intake, thyrotoxicosis, 
anxiety or psychosis. Therefore, in addition to undertaking a thorough general medical 
assessment, laboratory (serum thyrotropin levels and full blood count) tests, a 12-lead ECG 
and ambulatory cardiac rhythm monitors are required. The latter may be in the form of 24-
hour, 48-hour, 7-day or longer ambulatory monitors which may reveal occult arrhythmias or 
allude to non-physiological phenomena such as lack of nocturnal vagal predominance. In 
accordance with expert consensus, the clinical diagnosis is made, after exclusion of 
differentials,  in symptomatic patients with a persisting daytime sinus tachycardia 
 
Differential Diagnosis 
Certain cardiac supraventricular tachycardias (SVT), which are amenable to curative 
treatment, may present with similar symptoms to IST. Electrocardiographic examples are 
shown in Figure 1 [Figure 1]. Accessory pathway mediated SVT and atrioventricular nodal 
re-entry tachycardia (AVNRT) almost always have a sudden onset and offset. The 12-lead 
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ECG in AVNRT is usually normal at baseline and subtle retrograde conducted P-waves are 
often seen during SVT. Accessory pathways may result in typical delta waves and short PR 
duration at baseline if conducting in the anterograde direction, and therefore it is manifest. 
Generally, if the accessory pathway conducts in the retrograde direction, features of pre-
excitation are absent at baseline, and therefore it is concealed. Accessory pathway 
mediated SVT may be broad or narrow QRS complex, depending on the directionality of 
pathway conduction during SVT. One important pre-excitation syndrome mostly affecting 
children and teenagers is the permanent form of reciprocating junctional tachycardia (PJRT). 
This incessant form of long RP SVT commonly utilises an accessory pathway which is located 
in the right inferior paraseptal region and is often drug refractory. Its chronic nature and 
tachycardia rates as low as 130bpm may mask the diagnosis for months and subsequently 
promote a tachycardia-mediated cardiomyopathy. The latter is reversible after accessory 
pathway ablation(13) (14).  
Atrial tachycardia (AT) on the other hand may oftentimes be difficult to differentiate from 
IST, particularly when arising from areas adjacent to the sinus node, such as superior crista 
terminalis or even within the sinus node in the form of re-entry. Although 12-lead ECG P 
wave axis and morphology will often provide vital clues to the AT site of origin, an AT focus 
close to the sinus node will generate a P wave morphology very similar or identical to that of 
sinus rhythm. The onset of tachycardia and symptoms, in addition to other clinical features, 
may point to either IST or AT.  
Another condition to consider is Postural Orthostatic Tachycardia Syndrome (POTS), as both 
POTS and IST have overlapping clinical features. This increasingly recognised disorder is a 
condition of autonomic dysfunction characterised by a hyperadrenergic response to 
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orthostatic change in posture, with symptoms of dizziness, pre-syncope and diaphoresis 
(15). An exaggerated HR response to isoprenaline may be seen in both IST and POTS, and 
therefore a detailed clinical assessment is required to demonstrate the orthostatic 
relationship to symptoms and HR changes which occur in POTS. A head up tilt table test may 
be useful in demonstrating a 30 bpm HR rise (or tachycardia >120 bpm) on assuming the 
upright position from being supine. In the supine position, the 12-lead ECG in  POTS patients 
is rarely >100 bpm whereas in IST the resting HR is often >100 bpm.  
 
Conventional Management Strategies for IST 
The use of negative chronotropic agents such as beta-blockers and calcium antagonists is 
often unsuccessful in controlling IST symptoms and HR(16). Intolerance to beta-blockade 
side effects may be particularly troublesome in this patient group. Clinicians have 
occasionally trialled beta adrenoceptor antagonists with intrinsic sympathetic activity (for 
example, pindolol or acebutolol). The goal with this approach is to supress elevated HR 
whilst minimising anti-adrenergic related adverse effects. However, there is no evidence 
supporting an advantage for beta-blockers with intrinsic sympathetic activity over pure 
beta-blockers. There is an identified overlap of IST in some instances with anxiety disorders, 
which may also require specific treatment(1).  
Invasive techniques are reserved for patients highly debilitated by drug-refractory 
symptoms. Limited experience exists for surgical or radiofrequency catheter modification of 
the sinus node zone in these patients. The effectiveness of catheter ablation in IST is at best 
modest. At an experienced centre, after a mean follow-up of 4 months, symptoms recurred 
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in 27% of patients deemed to have acute procedural success(17). Long term symptom 
control was not achieved in one third of patients despite repeat procedures. The risk of 
complications is low but not non-trivial. Sinus node dysfunction requiring permanent pacing, 
right phrenic nerve injury and superior vena cava syndrome are uncommon but serious 
complications.  
The ablate and pace strategy is often undesirable in view of the sacrifice of atrio-ventricular 
conduction and complete reliance on permanent pacing in this younger demographic. 
 
Ivabradine 
Overview of Ivabradine 
Ivabradine is a novel selective inhibitor of cardiac ionic channels which results in negative 
chronotropic effects through a reduced sinoatrial depolarisation rate, with negligible effects 
on contractility. The agent has been approved in Australia since 2006 primarily as a second 
line agent for patients with chronic stable angina who are intolerant of, or have a 
contraindication to beta-blockers, or as add-on therapy to beta-blockers in patients with 
inadequately controlled HR. The drug has been studied for its quantitative impact on 
exercise tolerance in patients with coronary artery disease and for its role in the treatment 
of chronic systolic (impaired ejection fraction) heart failure(18-23). Currently, Ivabradine is 
only covered by the Pharmaceutical Benefit Scheme (PBS) for its use in Heart failure and 
although approved for use in angina, this is currently only as a private prescription. In 
addition, emerging evidence has shown ivabradine to be of potentially significant benefit in 
patients with IST(24-26). 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Pharmacology of Ivabradine 
Sinoatrial nodal cells have an innate automaticity involving a slow inward current of sodium 
(and calcium), coupled with a slowly diminishing outward potassium current. This results in 
a cyclical drift of the resting membrane potential towards depolarization threshold, and is 
known as the pacemaker or “funny” current (If) [Figure 2]. It was dubbed “funny” because of 
its unique characteristics when compared to other cardiac membrane channels. The If  
current is mostly generated through a non-selective voltage gated transmembrane cation 
channel known as the Hyperpolarization-activated cyclic nucleotide gated (HCN4) channel, 
which is strongly expressed in the sinus node region. Ivabradine is a chiral molecule with 
only the S-enantiomer showing voltage-dependent affinity to the HCN4/If channel. Accessing 
the intracellular aspect of the channel, the drug blocks the transmembrane channel pore, 
selectively inhibiting inward cation movement. This slows the rate of pacemaker 
depolarization and thereby reduces sinus node beating rate with no appreciable effects on 
myocardial repolarisation or contractility. Ivabradine does not affect the QT interval on the 
surface electrocardiogram (ECG). In addition to a neutral effect on myocardial inotropy, no 
measurable changes are observed in systemic vascular resistance, cardiac output or 
coronary perfusion pressure. At therapeutic doses (5-7.5 mg twice daily oral dosing), resting 
and exertional HR are reduced by approximately 10 bpm, with a ceiling effect at doses of 20 
mg twice daily. In the absence of food, an oral dose has only about 40% bioavailability due 
to extensive first pass hepatic metabolism by cytochrome P450 (CYP) 3A4. Potent CYP3A4 
inhibitors such as macrolide antibiotics, azole antifungals and protease inhibitors may 
increase plasma levels. Additionally, concomitant use of moderately potent CYP3A4 
inhibitors such as diltiazem and verapamil may result in a combined pharmacokinetic 
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(increased serum Ivabradine) and pharmacodynamic (potentiation of bradycardia effect) 
interaction.  
Ivabradine is a weak inhibitor of CYP3A4 and is therefore unlikely to influence metabolism of 
other drugs, or their plasma levels. Food delays absorption but increases peak plasma levels 
and overall bioavailability to 70%. Trough plasma levels occur 12 hours after the last dose 
and on that basis, clinical studies into its quantitative effect on exercise tolerance are 
performed at this nadir state.  
Contra-indications and adverse reactions 
Ivabradine is generally contraindicated in the presence of resting bradycardia (<60 bpm), 
hypotension, and in sinus node dysfunction. Atrioventricular (AV) nodal disease is a relative 
contraindication however the drug may be used with caution in first and second degree AV 
block. Due to the lack of clinical studies into its safety or efficacy in atrial or ventricular 
tachyarrhythmias, Ivabradine should generally be avoided in those conditions. Finally, in 
conditions that predispose to an acquired long QT interval, Ivabradine should be avoided or 
used with careful monitoring to prevent excessive bradycardia and exacerbation of the 
polymorphic ventricular tachycardia risk.  
Ivabradine is shown to be well tolerated, with dose-dependent predictable adverse 
reactions. The most common cardiovascular adverse reactions are bradycardia and 
hypotension whereas visual disturbances are the most common non-cardiovascular effects. 
Bradycardia (<60 bpm) was estimated at 4.2% in a randomised clinical study(31). This is 
comparable to but somewhat lower than the prevalence of bradycardia noted for the beta 
adrenoceptor antagonist, atenolol (5.8%). The combination of beta-blocker and Ivabradine 
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use results in an additive risk of bradycardia, with the SIGNIFY study showing a prevalence 
of 17.9% in a randomised double-blind multi-centre clinical trial setting(19). The most 
common adverse reaction overall is a phenomenon of visual phosphenes (14.5%)(27). This 
consists of bright illuminations at the periphery of the visual field exacerbated by sudden 
changes in the ambient level of brightness. This peculiar effect appears to be benign with 
the vast majority of patients reporting a mild to moderate level of intensity. The condition is 
self-resolving in >75% of patients within a matter of months without dose modification or 
treatment interruption(27). Less than 1% of patients reported having to stop treatment or 
modification of their daily activities to accommodate for this visual disturbance. 
Role of Ivabradine in IST 
With the development of ivabradine and insights into its pharmacologic mechanisms, some 
experimental use in IST has emerged(25). Early pilot work demonstrated the effectiveness of 
Ivabradine in reducing minimum, mean and maximum HR in addition to symptom 
improvement or complete resolution(27). In addition, the drug appeared to be well 
tolerated.  
Several non-randomised open label studies of short to intermediate follow-up duration 
showed scope for the efficacy and tolerability of Ivabradine in IST. In 2010, an open label 
efficacy study in 18 subjects showed the drug to be well tolerated and associated with a 
significant reduction in maximal and median HR as well as greater workloads achieved on 
standard treadmill stress testing. One patient was excluded from the study due to persistent 
phosphene visual effects despite dosage reduction(23).  
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In 2012 a small randomised and placebo controlled cross-over study compared Ivabradine 
to placebo in 21 patients with IST(28). After 6 weeks of therapy, patients taking Ivabradine 
(either 5 mg or 7.5 mg twice daily) experienced a 12 bpm reduction in resting HR, 18 bpm 
reduction on exercise, 16 bpm reduction on standing and 11 bpm reduction in mean 24 
hour HR. These statistically significant improvements were associated with improved 
exercise tolerance and a quantitative reduction in symptom severity of >70%. Overall, more 
than 45% reported complete resolution of symptoms. In 2013, a study comparing long 
acting metoprolol (succinate) to Ivabradine in 20 patients was performed assessing changes 
in HR and quantitative symptomatology(16). Patients who had IST refractory to traditional 
beta-blockers were switched from metoprolol succinate to Ivabradine after 4 weeks of 
therapy. Although mean 24 hour HR reduction was similar between both agents, Ivabradine 
showed a greater reduction in daytime HR reduction. The metoprolol group experienced 
significantly greater troublesome bradycardia and hypotension requiring dosage reduction. 
Using an IST specific symptomatology scoring algorithm, Ivabradine treatment showed 
superior symptom attenuation as compared with metoprolol succinate.   
An open label study of longer duration in 2013 showed favourable results and in addition, 
cessation of the drug after 1 year of therapy was associated with maintained HR benefits in 
80% of patients(29). The latter observation points towards a possible mechanism beyond 
symptom suppression only but may represent prevention of the disease progression 
through favourable functional and/or structural cardiac remodelling. 
The Ivabradine Versus Beta-blockers in the Treatment of Inappropriate Sinus Tachycardia 
(CIBIST; Clinical Trials Identifier NCT01657136) is an open label non-randomised study 
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comparing Ivabradine to the long half-life beta-blocker, bisoprolol. The phase III study 
primary outcome of HR reduction is expected to be released in 2016. 
Table 1 shows key findings of several important studies of different IST management 
modalities. 
Guideline Recommendations for IST Management 
The last focused ACC/AHA/ESC supraventricular arrhythmia guidelines in 2003 provided a 
class I recommendation for beta blockers, class IIa for calcium channel blockers and class IIb 
for catheter ablation, noting that all three treatments had level C evidence(30). However in 
2015 the Heart Rhythm Society (HRS) expert consensus statement assigned a Class IIa 
recommendation for the use of ivabradine with level B-R evidence (moderate randomised 
trial) and removed recommendations for other pharmacotherapies. In addition, catheter 
ablation was actively recommended against with level E (consensus) evidence(5). 
Cost Implications if Ivabradine was subsidised for use in IST 
Inappropriate sinus tachycardia is an uncommon condition. Epidemiological estimates from 
Still et al put the prevalence at 1.16% with preponderance in middle aged adults (mean age 
47±7 years)(4). Based on this and the comparative study between Ivabradine and 
Metropolol succinate, we provide a crude estimate of cumulative costs incurred for funding 
of Ivabradine by the PBS. The PBS is a program of the Australian Government that provides 
subsidised prescription drugs to residents of Australia. Of the 15.9 million Australians aged 
15-65 years of age (Australian Bureau of Statistics, 2010), 184,440 individuals could feasibly 
satisfy conventional diagnostic criteria for IST. Based on comparative data from Ptaszynski 
et al(16), we posit that considering a worst case scenario, 50% of patients being treated for 
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IST could require step-up therapy from either beta-blockade or calcium antagonists to 
Ivabradine. The Food and Drug Administration of the United States recently approved 
Ivabradine for patients who have symptoms of heart failure that are stable with a resting HR 
of at least 70 beats per minute and are also taking beta-blockers at the highest dose they 
can tolerate. The European Medicines Agency had set the cut-off HR at 75 beats per minute 
for the same indication. In Australia, Ivabradine is approved for use in refractory chronic 
stable angina and chronic systolic heart failure. Current PBS subsidy indications for 
Ivabradine are for NYHA class II or III systolic heart failure (LVEF < 35%) in sinus rhythm, with 
a HR ≥77 beats per minute, despite maximum tolerated beta-blocker dosage. Economic 
recommendations submitted by Servier Laboratories Australia Pty Ltd to the PBS Advisory 
Committee (July 2012) for funding of Ivabradine for systolic heart failure, estimated a net 
cost to the government at $10-30 million by 5 years of listing. The incremental cost 
effectiveness ratio (ICER) expressed as a cost/quality adjusted Life Year (cost/QALY) is 
conservatively estimated at 65% for Ivabradine. In 2007-08, the prevalence of ischaemic 
heart disease and cardiac failure were 685,000 (Australian Institute of Health and Welfare 
[AIHW], 2012) and 276,250 (AIHW, 2011) respectively. Therefore, the $10-30 million 5 year 
cost for funding Ivabradine for the 961,250 patients with ischemic heart disease or cardiac 
failure may be used to model the anticipated costs for funding Ivabradine for the estimated 
92,220 symptomatic patients with IST refractory to currently used pharmacotherapy (beta 
blockers and calcium channel antagonists). This 5 year estimate would be $1-2.9 million. It 
should be emphasized that the availability of Ivabradine as a potentially efficacious 
treatment option for IST would likely negate the need for invasive radiofrequency catheter 
modification of the sinus node, subsequently offsetting invasive treatment costs in patients 
with refractory symptoms. Moreover, in our experience, efficacious treatment in this 
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younger patient population can reduce indirect economic costs associated with the number 
of sick days, unemployment and disability claims.    
 
Conclusion 
Inappropriate sinus tachycardia is a condition with a best estimate prevalence of 1.16% in 
the general adult population. The condition has a wide spectrum of symptom severity and 
due to its predilection in the young, it has the potential to adversely impact daily activities, 
particularly effort tolerance and personal economic productivity, despite its overall benign 
course. Whilst it remains ill-defined on a cellular level, it appears that IST is probably a sinus 
node channelopathy in origin rather than a disease of altered autonomic modulation (as 
opposed to POTS, an important differential diagnosis). The mainstay of therapy has been 
beta-blockers. Despite some effect at reducing HR, these agents appear to have limited 
benefit and a significant adverse effect profile  in this active younger group of patients. 
Catheter ablation remains an evolving technique with modest results despite multiple 
procedures. In small clinical studies, Ivabradine has shown benefit in HR reduction, 
quantitative improvement in exercise capacity and subjective symptom burden 
amelioration. The drug is well tolerated and appears to carry a lower proarrhythmia risk. For 
a chronic condition often becoming clinically problematic in management, Ivabradine shows 
much promise as a potential therapy of choice for beta-blocker intolerant or sub-optimally 
responsive patients. Currently there are no large prospective randomised double-blinded 
placebo controlled studies examining the efficacy of the various treatment modalities. 
However the updated Heart Rhythm Society guidelines recommending Ivabradine with Class 
IIa, Level B-R evidence, reflects the progressively accruing evidence base for its use above all 
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other conventional treatment options. Given the low prevalence of IST and evidence for 
significant physiological and functional improvement with ivabradine, when considering 
suitability for prescription subsidy, ivabradine may well represent a cost-effective and 
relatively inexpensive treatment option.  
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Figure legend  
Figure 1: Electrocardiographic examples showing important differential diagnoses for 
Inappropriate Sinus Tachycardia. A. An example of the permanent form of junctional 
reentrant tachycardia is shown. In this example, antegrade (atria to ventricles) conduction 
occurs through the atrioventricular node (AVN) and retorograde conduction (ventricles to 
atria) through the accessory pathway. Retorograde conduction is relatively slow resulting in 
a long RP interval. This is most obvious in leads II and aVF. B. An example of the most 
common form of AV node reentrant tachycardia is shown. Retrograde conduction is very 
rapid, resulting in a P wave deforming the terminal portion of the QRS complex. This 
manifests as a pseudo-r’ in V1 and pseudo-s’ in II, III and aVF. C. An example of ventricular 
pre-excitation is shown with conduction over an atrioventricular accessory pathway fibre. 
This results in an abbreviated PR interval and a delta wave (slurred QRS upstroke). D. An 
example of focal atrial tachycardia is shown. Like A, this is also a long RP tachycardia. The 
specific P wave morphology and polarity will depend on the precise location of the focus 
along the crista terminalis.  
Figure 2: Overview of sinus node action potential profile. The pacemaker potetial (diastolic 
depolarization, If funny current) is responsible for the slow drift of the membrane potential 
(millivolts, mV) towards threshold (-40 mV). Once threshold is reached, rapid inward calcium 
(ICa) movement triggers membrane depolarization. Potassium efflux (Ik) subsequently 
repolarizes the membrane back towards subthreshold potential. Ivabradine accesses the 
cytoplasmic aspect of the If channel, specifically inhibiting the pacemaker potential. 
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Table 1: Major studies of Ivabradine for the treatment of IST 
Author Study Design Population Key Findings 
Whalley, 
2006(27) 
Open label prospective 
evaluation. Treatment 
with Ivabradine and 7 
months follow-up 
7 patients with IST 
refractory to ≥2 drugs 
Compared to baseline, 
significant reduction in mean, 
minimum and maximum 24 
hour HR. Significant 
improvement in quality of life 
scores 
Cappato, 
2012(28) 
Prospective randomized 
double-blind placebo-
controlled cross-over 
evaluation. 
Treatment with placebo 
or Ivabradine for 6 weeks 
then cross-over 
21 patients with IST 
Compared with placebo, 
Ivabradine significantly 
reduced supine and 
orthostatic HR; reduced 
mean, minimum and 
maximum HR; increased 
exercise expenditure 
capability; reduced symptom 
severity scores 
Ptaszynski, 
2013(16) 
Open label prospective 
evaluation. Treatment 
with metoprolol succinate 
for 4 weeks followed by 
Ivabradine 
20 patients with IST 
resistant to previous 
therapy with either 
metoprolol tartarate or 
verapamil 
Compared to metoprolol 
succinate, Ivabradine showed 
greater reduction in mean 24 
hour HR, greater reduction in 
symptom severity scores and 
greater increase in exercise 
tolerance with treadmill 
stress testing 
Benezet-
Mazuecos, 
2013(29) 
Open label prospective 
safety and efficacy study. 
Treatment with 
Ivabradine twice daily, 5 
mg or 7.5 mg dosage 
24 patients with IST 
treated with Ivabradine 
and followed-up for 12 
months 
Ivabradine treatment 
significantly reduced 
(normalised) mean, maximum 
and minimum HR, and 
significant improvement in 
quality of life scores. At 12 
months, 80% of patients 
remained free of IST criteria 
despite stopping the 
medication 
Calo, 
2010(23) 
Open label prospective 
safety and efficacy study 
16 patients with IST  
treated with Ivabradine 
and followed-up for 6 
months 
Compared to baseline, 
Ivabradine significantly 
reduced mean and maximum 
HR. Ivabradine increased 
exercise capacity on treadmill 
testing 
    
Table 1: Symptoms assessed by SF36 and/or European Heart Rhythm Association symptom score grades (I-IV). Heart rate 
trends assessed by 24 hour Holter monitoring. Metoprolol tartarate is a rapid acting twice daily dosed beta-blocker, 
whereas the succinate salt is the slow release once daily dosed formulation. HR: Heart Rate 
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Figure 1: Electrocardiographic differential diagnoses for Inappropriate Sinus Tachycardia 
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Figure 2
 
 
 
 
 
 
 
: Overview of sinus node action potential profile. 
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